Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease

MT Newswires Live
昨天

Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.

The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.

The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.

LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10